Eversept Partners’s Humacyte HUMA Stock Holding History

Eversept Partners’s Portfolio HUMA Stock Details HUMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-205,026	Closed	-$2.09M	–	112
2021 Q2	$2.09M	Sell	205,026 -34,000	-14%	-$350K	0.14%	68
2021 Q1	$2.59M	Buy	+239,026	New	+$2.61M	0.19%	58

Other funds holding HUMA

YCMGA

York Capital Management Global Advisors New York $87.8M AUM 45.55% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

DCP

Diameter Capital Partners New York $1.07B AUM 152.29% 1-Year Est. Return

MIM

Monashee Investment Management Boston, Massachusetts $184M AUM 197.43% 1-Year Est. Return

CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return

Maven Securities St Helier, Jersey $5.2B AUM 44.01% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Eversept Partners's HUMA Position: Q3 2021 in Review

Eversept Partners sold out of Humacyte (HUMA) in Q3 2021, closing a stake of 205,026 shares — an estimated $2.09M sold.

Eversept Partners first reported a position in HUMA in Q1 2021 and held it in 2 quarters. The position peaked at $2.59M in Q1 2021. 32 funds tracked by Wall St. Rank hold HUMA as of Q3 2021.

Eversept Partners reported no remaining Humacyte position as of Q3 2021 after selling out during the quarter.
Eversept Partners sold 205,026 Humacyte shares in Q3 2021, an estimated $2.09M.
Eversept Partners first reported a position in Humacyte in Q1 2021 and held it in 2 quarters.
Eversept Partners's Humacyte position peaked at $2.59M in Q1 2021.
32 funds tracked by Wall St. Rank held Humacyte as of Q3 2021.

Based on Eversept Partners's 13F filing for Q3 2021, filed 15 Nov 2021.